Navigation Links
DuoCort Hosts Adrenal Insufficiency Symposium at the 10th European Congress of Endocrinology in Berlin
Date:4/18/2008

HELSINGBORG, Sweden, April 14, 2008 / b3c newswire /   -  DuoCort AB announced today that it will host a satellite symposium – Optimized Care for Adrenal Insufficiency – at the 10th European Congress of Endocrinology (ECE 2008) at the Internationale Congress Centrum in Berlin.  The symposium will be held on Tuesday May 6, 1pm–2.30pm, in Hall 7.  All delegates attending ECE 2008 are invited to the symposium.

Prof emer Michael Besser will chair the symposium, which also features a number of other authorities in the field:  Dr John Newell-Price, Prof Brian R Walker, and Dr Gudmundur Johannsson, Chief Medical Officer of DuoCort.  The symposium will cover key aspects and recent developments in therapy for adrenal insufficiency, including choice of glucocorticoid and dosing, outcomes from current therapy, and ways to improve glucocorticoid replacement therapy. 

DuoCort is developing a once-daily dual-release hydrocortisone tablet for adrenal insufficiency.

In December 2007, DuoCort completed the targeted enrolment in the pivotal phase II-III clinical trial evaluating 5 mg and 20 mg DuoCort™ dual-release hydrocortisone tablets for the treatment of adrenal insufficiency – the inability of the body to produce sufficient amounts of the essential hormone cortisol. The first data from the study is expected to be available in Q3 2008.

“Current research confirms that conventional therapy is suboptimal and is not serving these patients as well as it should.  There is scope for improvement in the delivery of cortisol replacement and we are convinced DuoCort will deliver better long-term outcomes.  This trial is a major step toward offering a better treatment option for patients with adrenal insufficiency”, commented Dr Johannsson.

For more information about DuoCort and its drug development programs, contact Greg Batcheller, CEO, tel. +46 46 288 5008. www.duocort.com

Notes to the editor

About adrenal insufficiency
Recent research on adrenal insufficiency patients taking currently available glucocorticoid replacement therapy demonstrates reduced bone density, unfavourable cardiovascular risk profiles and compromised quality of life and well-being.  Recent data also suggest an almost 3-fold increased mortality. Improvement in the replacement regimen and replacement strategy is therefore essential. Chronic adrenal insufficiency is a rare disease that affects over 125,000 patients in the European Union and over 100,000 in North America.
 
About DuoCort™ dual-release hydrocortisone DuoCort™ dual-release 5 mg and 20 mg hydrocortisone tablets for patients with chronic adrenal insufficiency were granted an Orphan Medicinal Product Designation in the European Union in May 2006.  DuoCort’s objective is to improve today’s glucocorticoid replacement therapy with a tablet that delivers a more physiological profile of hydrocortisone, better mimicking the body’s natural cortisol release by combining rapid release and extended release characteristics.  DuoCort™ is a once-daily tablet that is more convenient than current therapy.

About DuoCort AB
DuoCort AB is a drug development company focused on improving glucocorticoid therapy in areas of significant unmet medical need. The company is based in Helsingborg, Sweden.
'/>"/>

b3c newswire

Related biology technology :

1. Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium
2. Pharsight Hosts Fourth Annual PKS User Group Meeting
3. Germany Hosts World Leading Medical Industry Fair
4. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
5. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
6. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
7. Stevens to host Nanoscience/Nanotechnology & Corrosion symposium, Nov. 13
8. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
9. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
10. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
11. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking ... initiative announced today. The bold new look is part of a transformation to ... into a significant growth period. , It will also expand its service offering from ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
Breaking Biology Technology:
(Date:8/15/2017)... Aug. 15 2017   ivWatch LLC , a medical device ... therapy, today announced receipt of its ISO 13485 Certification, the global ... International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection of ... "This is an important milestone ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
Breaking Biology News(10 mins):